Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Recruiting now Phase 1 NCT06451770
Run by Verve Therapeutics, Inc. · for 18 to 70 · All sexes
What this study is about
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Who can join (things the study team will check)
✅ You may be able to join if…
- Refractory hypercholesterolemia
- Refractory hypertriglyceridemia
🚫 You may not be able to join if…
- Active or history of chronic liver disease
- Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
Where this trial is running
- Clinical Study Center, Adelaide, Australia
- Clinical Study Center, Melbourne, Australia
- Clinical Study Center, Chicoutimi, Canada
- Clinical Study Center, Montreal, Canada
- Clinical Study Center, Toronto, Canada
- Clinical Study Center, Cape Town, South Africa
- Clinical Study Center, Johannesburg, South Africa
- Clinical Study Center, Liverpool, United Kingdom
- Clinical Study Center, London, United Kingdom
- Clinical Study Center, Manchester, United Kingdom
Who to contact
Clinical Development · 781-970-6833 · verve201clinicaltrials@lists.lilly.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06451770.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.